U.S. Markets close in 1 hr 54 mins

  • S&P 500

    4,533.91
    +14.28 (+0.32%)
     

  • Dow 30

    35,615.42
    +158.11 (+0.45%)
     

  • Nasdaq

    15,111.59
    -17.50 (-0.12%)
     

  • Russell 2000

    2,288.01
    +12.10 (+0.53%)
     

  • Gold

    1,785.60
    +15.10 (+0.85%)
     

  • EUR/USD

    1.1656
    +0.0019 (+0.1632%)
     

  • 10-Yr Bond

    1.6400
    +0.0050 (+0.31%)
     

  • Vix

    15.61
    -0.09 (-0.57%)
     

  • GBP/USD

    1.3827
    +0.0033 (+0.2420%)
     

  • USD/JPY

    114.2310
    -0.1290 (-0.1128%)
     

  • BTC-USD

    66,347.10
    +2,996.46 (+4.73%)
     

  • CMC Crypto 200

    1,544.01
    +63.20 (+4.27%)
     

  • FTSE 100

    7,223.10
    +5.57 (+0.08%)
     

  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

How the wine industry can attract African American consumers

Yahoo Finance's Julie Hyman, Sibile Marcellus and Ethan Wolff-Mann sit down with Larissa Dubose - The Lotus & The Vines Founder.

Recommended Stories

  • Pinterest soars as PayPal reportedly mulls acquisition

    Yahoo Finance's Emily McCormick discusses Pinterest stock surge amid reports that PayPal is mulling its acquisition.

  • Novavax falls on production delay report, but this analyst expects good sales in the future

    Oppenheimer analyst Hartaj Singh discusses the latest developments in the vaccine space, the state of biotech and why he thinks despite the recent selloff in Novavax, the company will deliver good sales in 2023 and beyond.

  • Tesla reports earnings on Wednesday — here's what to expect

    Emily McCormick breaks down what the Street is expecting ahead of Tesla’s third-quarter results, which the electric automaker is set to report after the bell on Wednesday.

  • Analyst calls Coinbase a 'must own' stock, sees price going to $600

    Lisa Ellis, MoffettNathanson Senior Equity Analyst, discusses Coinbase's new partnership with Facebook for new 'Novi' cryptocurrency wallet.

  • Sesen Bio Shares Gain On FDA Type A Meeting On Issues From Vicineum Response Letter

    The FDA has granted Sesen Bio Inc's (NASDAQ: SESN) request for a Type A meeting to discuss the Chemistry, Manufacturing, and Controls (CMC) issues raised in the Complete Response Letter for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer. Related: Sesen Bio Stock Crashes As FDA Shoots Down Its Bladder Cancer Pitch. The CMC Type A Meeting has been scheduled for October 29. The Company is also preparing for a separate Type A meeting to discuss the recommendations specific to addit

  • Why Ford Motor Company Stock Is Rising Today

    Shares of Ford Motor Company (NYSE: F) were moving higher on Wednesday morning, after a Wall Street analyst boosted his bank's rating on the stock in a bullish note. As of 11 a.m. EDT today, Ford's shares were up about 4% from Tuesday's closing price. In a new note on Wednesday morning, Credit Suisse Group analyst Dan Levy raised his bank's rating on Ford's stock to outperform, from neutral, and increased its price target to $20 from $15.

  • Novavax vaccine delays slump stock, Abbott Labs raises guidance, Biogen beats Q3 estimates

    Yahoo Finance's Brian Sozzi, Brian Cheung and Julie Hyman break down how Novavax, Biogen, and Abbott Labs are faring in Wednesday’s market

  • Spanx—Founded With $5,000—Is Now Worth $1.2 Billion in Blackstone Deal

    (Bloomberg) -- Sara Blakely founded Spanx Inc. in 2000 with $5,000 of her personal savings earned from selling fax machines door-to-door. She just struck a deal with Blackstone Inc. that values the company at $1.2 billion. Most Read from BloombergGoogle’s Biggest Moonshot Is Its Search for a Carbon-Free FutureA $30 Billion Fortune Is Hiding in China’s Silicon ValleyGoogle’s CEO: ‘We’re Losing Time’ in the Climate FightBeef Industry Tries to Erase Its Emissions With Fuzzy Methane MathHate-Speech

  • Why Canopy Growth, Tilray, and Hexo Stocks Dropped

    After glowing a healthy shade of green yesterday, marijuana stocks are wilting on Wednesday, with shares of Canopy Growth (NASDAQ: CGC) down 2.6%, Tilray (NASDAQ: TLRY) tumbling 2.8%, and Hexo (NASDAQ: HEXO) off a more disturbing 6.7% as of 11:30 a.m. EDT. News from Mexico, to be precise. Yesterday, investors snapped up shares of Canopy Growth, which rose 8.6%, and Tilray and Hexo as well -- up 15.8% and 14.8%, respectively.

  • Rio Tinto announces bold $7.5 billion spend to halve carbon emissions by 2030; shares fall

    MELBOURNE (Reuters) -Anglo-Australian miner Rio Tinto announced on Wednesday a $7.5 billion plan to reduce carbon emissions by 50% by 2030, a reduction three times greater than its previous target, but shares fell as investors reacted to the higher spend. As steel and iron ore producers continue their push to cut carbon emissions in line with global climate commitments by 2050, Rio said it sought to halve its scope 1 and 2 carbon emissions - direct emissions by the company and certain types of indirect emissions, respectively - by the end of the decade. Rio brought forward its target to 2025 for a 15% reduction in emissions from 2018 levels, five years faster than it had previously targeted.

  • Pinterest Q3 Earnings: Here's What to Look For

    Investors will be laser-focused on Pinterest's monthly-active-user trends when it reports Q3 earnings.

  • Exxon board debates dropping several major oil and gas projects - WSJ

    Activist investor Engine No. 1 in May shocked the oil-and-gas industry when three of its four nominees were elected to the board by Exxon shareholders, who were frustrated by weak returns and the company's flagging attention to climate concerns. The board members expressed concerns about some projects, including a $30 billion liquefied natural gas development in Mozambique and another multibillion-dollar gas project in Vietnam, the WSJ report said, citing people familiar with the matter. Exxon did not immediately respond to a Reuters request for comment.

  • NIO May Bring ET7's Electric Drive System To All Models: Report

    Chinese electric vehicle maker Nio Inc (NYSE: NIO) may introduce its electric sedan ET7’s electric drive system to all models, cnEVpost reported on Tuesday, citing a Chinese news publication. What Happened: The Shanghai-headquartered Nio may bring the second-generation electric motor to other models such as the ES8, ES6 and EC6, as per reports coming from China. The electric drive system has a combined system power of 480kW — 180kW at the front and 300kW at the rear — and a peak torque of 850 Nm

  • 3 Stocks Ready to Bounce Back

    The market has been unkind this year to some of the hottest growth stocks of 2020. Three such stocks are Teledoc Health (NYSE: TDOC), Peloton Interactive (NASDAQ: PTON), and Zillow Group (NASDAQ: ZG) (NASDAQ: Z).

  • Breakeven On The Horizon For Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

    Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ) is possibly approaching a major achievement in its business, so we would...

  • Here's Why Moderna's Growth May Be Just Getting Started

    Moderna (NASDAQ: MRNA) stock might look a bit expensive these days. At the same time, some investors wonder whether Moderna may have reached peak sales of its coronavirus vaccine. Right now, it's too early to predict if and when coronavirus vaccine sales will slow.

  • Biden revises proposal to have IRS monitor bank accounts more closely. Here’s how it would work

    After uproar over a proposal to have banks tell the Internal Revenue Service about their customers’ annual cash-flow information, the Biden administration and congressional Democrats unveiled a new, pared-down proposal on Tuesday. Now the question is whether this version of the proposed reporting requirement, which would kick in at the $10,000 mark instead of covering transactions above a $600 threshold, will, if it passes, win over critics and help the IRS catch tax cheats. In the Biden administration’s bid to ensure rich households pay their full tax bill, they proposed months ago that bank, loan and investment accounts report to the IRS on their customers’ aggregate “inflow” and “outflow” above the $600 point on a yearly basis.

  • Why Radius Health Stock Is Exploding Higher Today

    Shares of Radius Health (NASDAQ: RDUS), a biopharmaceutical company, are soaring today in response to positive clinical-trial data. Investors excited about elacestrant, an experimental new cancer treatment Radius Health is developing in partnership with the Menarini Group, an Italian company, pushed the stock up 48.8% shortly after the market opened. Elacestrant is an experimental therapy for breast cancer patients who have tumors that express lots of estrogen receptors but lack receptors for human epidermal growth factor.

  • BofA warns of 0% returns over the next 10 years — but here's the 1 key strategy to fight it

    The next decade could be a lost one — unless you do this.

  • 3 Under-the-Radar COVID Stocks

    What's really interesting about the stock market is there are always new companies trying new things. And sometimes the stocks of these companies come out of nowhere and blow the market averages away.